A comparative molecular analysis of DNA damage response, cell cycle progression, viability and apoptosis of malignant granulosa cells exposed to gemcitabine and cisplatin

[1]  I. Ray-Coquard,et al.  Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  I. Ray-Coquard,et al.  Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Arvas,et al.  Endogenous c-Jun N-terminal kinase (JNK) activity marks the boundary between normal and malignant granulosa cells , 2018, Cell Death & Disease.

[4]  E. Giovannetti,et al.  Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective , 2016, Cancer Chemotherapy and Pharmacology.

[5]  T. Esen,et al.  GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. , 2015, Human reproduction.

[6]  A. Iwase,et al.  The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. , 2015, Human reproduction.

[7]  U. Puistola,et al.  The clinical utility of serum anti‐Müllerian hormone in the follow‐up of ovarian adult‐type granulosa cell tumors—A comparative study with inhibin B , 2015, International journal of cancer.

[8]  A. Shelling,et al.  Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. , 2015, Gynecologic oncology.

[9]  M. Pike,et al.  The role of systemic chemotherapy in the management of granulosa cell tumors. , 2015, Gynecologic oncology.

[10]  C. Sessa,et al.  Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Ahmad.  Platinum–DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes , 2010, Chemistry & biodiversity.

[12]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[13]  W. Plunkett,et al.  H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation , 2007, Molecular Cancer Therapeutics.

[14]  T. Okumura,et al.  Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2004, Biochemical and biophysical research communications.

[15]  S. Cannistra,et al.  Granulosa cell tumor of the ovary. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Holzgreve,et al.  Characterization of an immortalized human granulosa cell line (COV434). , 2000, Molecular human reproduction.

[17]  C. L. Edwards,et al.  Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor. , 1998, Anti-cancer drugs.

[18]  R. Scully,et al.  Juvenile granulosa cell tumor of the ovary: A clinicopathological analysis of 125 cases , 1984, The American journal of surgical pathology.

[19]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.